Author: Latest update by Dr Alexis Daniel Lara Rivero, Dermatologist, Hospital Universitario de Caracas, Venezuela. Reviewed by Dr Margot Whitfeld, Dermatologist, Sydney, Australia. DermNet Editor in Chief: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. December 2017.
Mycetoma is a chronicinfection of the skin and the subcutaneous tissue. It can sometimes also affect muscles, bones, tendons and joints.
Mycetoma is characterised by nodules and sinus tracts that discharge watery fluid or pus containing grains [1].
Mycetoma is classified as:
Eumycetoma — when it is caused by a fungus;
Actinomycetoma— when it is caused by filamentous bacteria from the order, actinomycetes.
Mycetoma foot
Courtesy Dr. Sriyani Samaraweera
Actinomycetoma due to nocardia
Who gets mycetoma?
The bacteria and fungi causing mycetoma have a worldwide distribution in the soil and plant material, but mycetoma is mostly found in tropical areas in south and south-east Asia, Latin America and Africa. Most cases are reported in the ‘Trans-African mycetoma belt” from western Africa, including Senegal and Sierra Leone, to eastern Africa, including Somalia and Sudan [2,3].
Infection usually occurs after local trauma.
Eumycetoma mainly affects middle-aged men that work as herdsmen or farmers, especially when walking barefoot.
Mycetoma can also affect younger men and females.
Actinomycetoma can also be related to oral infections, teeth or gum disease.
Mycetoma has no known vector or animal reservoir, and there are no reports of infections transmitted from person to person [1,3].
What causes mycetoma?
The causative agent can be suspected from the colour of the grains.
The incubation time after inoculation of the microorganism until mycetoma is diagnosed ranges from months to years [2].
Actinomycetoma and eumycetoma have similar clinical features. However, actinomycetomas tend to be more aggressive and destructive, invading bones earlier.
Mycetoma starts as a localised swelling on an exposed site; two thirds arise on the foot.
The affected area has normal skin temperature and is often hyperpigmented.
Multiple firm nodules appear and start to drain spontaneously or following pressure.
The fluid discharged from sinus tract can contain the characteristic granular grains.
Local pain is mild or absent, and it worsens only in later stages with more subcutaneous tissue damage or with secondary bacterial infection.
Mycetoma has little effect on the general condition of the affected patient and fever is rare [2].
Atrophy of the disused limb (reduction in size and strength)
Pain.
These can be prevented by early diagnosis and proper treatment [4].
How is mycetoma diagnosed?
Mycetoma is suspected when there is a typical triad of symptoms and signs:
A painless firm subcutaneous mass
Multiple sinus tracts
A purulent or sero-purulent discharge that contains grains.
Dermoscopy may be useful for early stages of the disease detecting grains within skin lesions [5]. Grains are conglomerates of fungi or bacteria disposed radially (like sun rays).
Tissue for microscopy and culture is collected by:
Making a small incision and expressing the secretions;
Using a needle and syringe to withdraw fluid.
The colour of the grains can narrow the options of the causative bacterium or fungus. The grains are treated with potassium hydroxide (KOH) and then stained with Gram and PAS stains. On microscopy:
As some are slow-growing organisms, cultures at 25–30°C and 37°C are set for up to 6 weeks for both bacteria and fungi [1,6]. When it is difficult to identify the responsible organism, molecular techniques such as PCR (polymerase chain reaction) can be used [2].
Mycetoma cannot be cured without active treatment. It requires antibiotics (for actinomycetomas) or oral antifungals (for eumycetomas) for weeks, months or years. Damage to subcutaneous tissues (muscle, bones, joints or tendons) often persists, so local surgery (including amputation) and physiotherapy may be required [1,2].
Despite the need for prolonged treatment, prognosis is usually good with proper therapy. The longer the infection has been present prior to treatment, the more likely complications and disability will occur [4].
References
Zijlstra E, van de Sande W, Welsh O, et al. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis 2016; 16: 100–12. PubMed.
Nenoff P, van de Sande W, Fahal A, et al. Eumycetoma and actinomycetoma – an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy. J Eur Acad Dermatol Venereol 2015; 29: 1873 – 83. DOI: 10.1111/jdv.13008. PubMed.
Van de Sande W. Global burden of human mycetoma: A systematic review and meta-analysis. PLoS Negl Trop Dis 2013; 7: e2550. DOI: 10.1371/journal.pntd.0002550. Journal.
Wadal A, Elhassan T, Zein H, et al. Predictors of post-operative mycetoma recurrence using machine-learning algorithms: the mycetoma research center experience. PLoS Negl Trop Dis 2016; 10: e0005007. DOI: 10.1371/journal.pntd.0005007. Journal.
Reis L, Lima B, Zillo F, et al. Dermoscopy assisting the diagnose of a mycetoma: case report and literature review. An Bras Dermatol 2014; 89: 832 – 3. DOI: 10.1590/abd1806-4841.20143008. PubMed Central.
Van de Sande W, Fahal A, Goodfellow M, et al. Merits and pitfalls of currently used diagnostic tools in mycetoma. PLoS Negl Trop Dis 2014; 8(7): e2918. DOI: 10.1371/journal.pntd.0002918. Journal.